GlassScriptPhysician profile
Amy M Bustin
NPI 1982643920
$5,050.36
in general payments reported to CMS, 2019-2025
37 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.41 · 2022: $279 · 2023: $1,215 · 2024: $1,720 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.39 | 2021-2025 | |
| Sk Life Science, INC. | $580.45 | 2023-2025 | |
| Lilly USA, LLC | $317.72 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $288.08 | 2023-2025 | |
| Mdd US Operations, LLC | $236.79 | 2023-2025 | Gocovri, Apokyn |
| Amgen INC. | $233.06 | 2022-2025 | Repatha, Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $207.97 | 2024 | Hyqvia |
| Amneal Pharmaceuticals LLC | $205.98 | 2024-2025 | Rytary, Ongentys, Crexont |
| Acadia Pharmaceuticals INC | $193.54 | 2024-2025 | Nuplazid |
| Argenx US, INC. | $192.70 | 2024-2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $157.89 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ceribell, INC. | $144.30 | 2025 | Pocket Eeg Device |
| Alexion Pharmaceuticals, INC. | $134.83 | 2021-2025 | Ultomiris, Soliris |
| Sumitomo Pharma America, INC. | $128.74 | 2023 | Aptiom |
| Genentech USA, INC. | $97.15 | 2023 | Ocrevus |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $90.21 | 2024-2025 | Ingrezza |
| Celgene Corporation | $88.06 | 2023-2025 | Zeposia |
| Lundbeck LLC | $86.34 | 2024-2025 | Vyepti |
| Ucb, INC. | $66.90 | 2022-2025 | Nayzilam |
| Astrazeneca Pharmaceuticals LP | $60.36 | 2024-2025 | Wainua |
| Averitas Pharma INC. | $59.20 | 2023-2024 | Qutenza |
| Jazz Pharmaceuticals INC. | $57.14 | 2023-2025 | |
| Ge Healthcare | $57.06 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $55.72 | 2023-2025 | Xeomin, Inbrija |
| Sunovion Pharmaceuticals INC. | $53.37 | 2022 | |
| Acorda Therapeutics, INC | $41.91 | 2024 | Inbrija |
| Eisai INC. | $41.51 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $39.33 | 2024-2025 | Rexulti |
| Csl Behring | $34.85 | 2023 | Hizentra |
| Inspire Medical Systems, INC. | $24.94 | 2024 | Inspire |
| Grt US Holding, INC. | $23.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.62 | 2022 | |
| Emd Serono, INC. | $20.30 | 2024 | |
| Collegium Pharmaceutical, INC. | $18.75 | 2023 | Belbuca |
| Novartis Pharmaceuticals Corporation | $18.16 | 2023 | |
| Upsher-Smith Laboratories LLC | $17.78 | 2023 | |
| Biogen, INC. | $14.71 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.